

## REVIEW

**Seshma Ramsawak, MD**

Department of Kidney Medicine,  
Cleveland Clinic, Cleveland, OH

**Scott Cohen, MD**

Department of Kidney Medicine,  
Cleveland Clinic, Weston, FL

**Andrea Linares, DO**

Department of Kidney Medicine,  
Cleveland Clinic, Weston, FL

**Corey Cavanaugh, DO**

Department of Kidney Medicine,  
Cleveland Clinic, Cleveland, OH; Assistant  
Professor, Cleveland Clinic Lerner College of  
Medicine of Case Western Reserve University,  
Cleveland, OH

# IgA nephropathy: Update on pathogenesis and treatment

## ABSTRACT

The pathogenesis of immunoglobulin (Ig) A nephropathy is described through a “4-hit” model involving production of galactose-deficient IgA, production of autoantibodies to galactose-deficient IgA, and subsequent deposition of immune complexes in the kidney glomerulus. Diagnosis remains dependent on a kidney biopsy, often after hematuria or proteinuria is detected on urinalysis. The cornerstone of therapy still involves renin-angiotensin-aldosterone system inhibitors or corticosteroids; however, new therapies targeting key aspects of the pathogenesis of IgA nephropathy are being introduced.

## KEY POINTS

IgA nephropathy is a relatively common autoimmune glomerular disease that can be diagnosed only by biopsy.

Proteinuria reduction remains the most important treatment target.

Treatment now includes sodium-glucose cotransporter 2 inhibitors and endothelin receptor antagonists in addition to renin-angiotensin-aldosterone system inhibitors and corticosteroids.

New therapies target multiple pathogenic “hits” to reduce proteinuria and preserve kidney function.

A MAJOR CAUSE OF KIDNEY FAILURE in children and adults, immunoglobulin (Ig) A nephropathy is the most common primary glomerulonephritis; its worldwide incidence is at least 2.5 per 100,000.<sup>1</sup>


There has been a tremendous lag in the treatment of the disease since its histologic features were first described in 1968 by Berger and Hinglais.<sup>2</sup> For decades, nephrologists have had little more than renin-angiotensin-aldosterone system (RAAS) inhibitors or corticosteroids in their treatment armamentarium. Thanks to a recent transformation in our understanding of and therapeutic approach to IgA nephropathy, in the near future, there may be more therapeutic options for IgA nephropathy than for any other glomerular disease. Opportunities for new therapies stem from the acknowledgment by the US Food and Drug Administration (FDA) that proteinuria reduction is an acceptable trial end point<sup>3</sup> in the path to drug approval. This recent innovation is also a direct consequence of years of basic science research that has refined our understanding of the pathogenesis of IgA nephropathy into a framework of “4 hits,” with each hit representing a target of novel therapies.

This review addresses the current approach to management of IgA nephropathy and therapeutic options we can soon expect.

## ■ THE 4 HITS OF IgA NEPHROPATHY

IgA nephropathy is an autoimmune disease of mucosal type IgA<sup>1</sup> characterized by deposition of immune complexes in the glomerulus. Its pathogenesis is now firmly established and understood as the 4-hit hypothesis (**Figure 1**).<sup>1</sup> The

doi:10.3949/ccjm.92a.24105



**Figure 1.** Pathogenesis of immunoglobulin (Ig) A nephropathy: the “4-hits” hypothesis.

4 hits comprise a complex interplay of genetic factors (involving polymorphisms in human leukocyte antigen, complement, and gut mucosal immunity) and environmental factors such as the gut microbiome, all of which contribute to the development of IgA nephropathy.

## Hit 1: excessive production of galactose-deficient IgA1

Galactose-deficient IgA1 in IgA nephropathy lacks the terminal galactose moieties at the hinge region of the molecule.<sup>1,4</sup> The primary site for production of galactose-deficient IgA1 is now believed to be the gut and nasal mucosa.<sup>2</sup> Many factors have been implicated in the production of galactose-deficient IgA1.

**Genetics** may influence the O-galactosylation of the IgA hinge region.<sup>5</sup> Abnormal galactosylation of IgA can be an inherited trait, but this alone is insufficient for development of IgA nephropathy.

**Cytokines**, including serum B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), are important regulators of mucosal B-cell survival and proliferation. BAFF and APRIL promote the formation of galactose-deficient IgA1-producing plasma cells in the mucosa.<sup>6</sup>

**Alterations in the composition of the gut microbiome** (which communicates with mucosal-associated lymphoid tissue) have been implicated in IgA nephropathy.<sup>7</sup> Mucosal dysbiosis may be related to dysregulated mucosal IgA synthesis. Recently, it was shown that patients with IgA nephropathy have a relative over-

growth of mucin-degrading bacteria,<sup>8</sup> which are capable of deglycosylating IgA1.

## Hit 2: production of autoantibodies to galactose-deficient-IgA1

Antibodies, either IgG or IgA, recognize the galactose-deficient hinge region of galactose-deficient IgA1, a neoepitope.<sup>1</sup> Routine immunofluorescence on kidney biopsy detects IgA bound to galactose-deficient IgA1 as the predominant immune complex deposited; however, evidence supports the presence of IgG autoantibodies, which also play a role in the pathogenesis of the disease.

## Hit 3: formation of immune complexes consisting of IgG autoantibodies bound to galactose-deficient IgA1

Clinical and histologic activity correlate with the level of circulating immune complexes.<sup>1,4</sup> Additionally, alternative complement and terminal complement activity have been shown to correlate with the concentration of galactose-deficient IgA1.

## Hit 4: deposition of immune complexes into the glomerulus

The effect of the immune complexes on mesangial cells within the glomerulus drives kidney injury.<sup>9,10</sup> Deposition of immune complexes activates mesangial cells, leading to production of inflammatory molecules such as interleukin-6 and platelet-derived growth factor and complement, which signal infiltration of monocytes and mediate glomerular injury.

**TABLE 1**  
**Immunoglobulin (Ig) A nephropathy and its mimics**

	IgA nephropathy <sup>1,12</sup>	Systemic IgA vasculitis <sup>1,12</sup>	IgA-dominant postinfectious glomerulonephritis <sup>13</sup>	Proliferative glomerulonephritis with monoclonal IgA deposits <sup>14</sup>
Clinical presentation	Varied, can present with a range of clinical syndromes: microscopic hematuria (more common than macroscopic), acute kidney injury, rapidly progressive glomerulonephritis, macroscopic hematuria with concurrent respiratory or gastrointestinal infection (ie, synpharyngitic hematuria)  Involvement limited to kidneys	More common in children  Extrarenal involvement (leukocytoclastic vasculitis; rash; joint pain; gastrointestinal, pulmonary, neurologic involvement)	Older adults, hypocomplementemia, acute kidney injury with hematuria and proteinuria	Rare; involvement limited to kidneys
Kidney biopsy	Dominant mesangial IgA staining on immunofluorescence microscopy with variable IgG staining and frequent C3 staining; chunky, irregular mesangial IgA staining on immunofluorescence  Polyclonal light chain deposition with lambda more intense than kappa		Endocapillary hypercellularity, often with neutrophils, on light microscopy  Dominant IgA staining with dominant or codominant C3 staining and absent or weak IgG staining; chunky, irregular mesangial IgA staining; lambda not dominant light chains on immunofluorescence microscopy  Subepithelial hump-shaped immune deposits on electron microscopy	Membranoproliferative pattern on light microscopy  Monotypic light chain deposition of IgA kappa more intense than lambda
Pathogenesis	4-hit model		Unclear: likely a host-pathogen interaction with superantigens stimulating host T-cell response	Unclear: rarely associated with malignancies despite monoclonal deposition of IgA
Associations	Primary and secondary <sup>a</sup> distinguished by presence of associated systemic disease	Upper respiratory or gastrointestinal infection	<i>Staphylococcus aureus</i> infection, diabetes	Myeloma (rarely)

<sup>a</sup>Common secondary: liver disease, celiac disease, inflammatory bowel disease, viral (human immunodeficiency virus, hepatitis B and C), ankylosing spondylitis, rheumatoid arthritis, systemic lupus erythematosus, psoriasis, Sjögren syndrome, tumors (lung, renal, lymphoma).

Based on information from references 1,12–14.

### The role of complement

Complement plays a prominent role in mesangial injury and is a major driver of glomerular inflammation.<sup>11</sup> C3 is deposited in the mesangium, activating both

the alternative and lectin pathways. In vitro studies provide evidence of alternative pathway proteins such as complement components C5, C6, and C9 and other membrane attack complex antigens in the glomeruli

of patients with IgA nephropathy, whereas markers for classical pathway activation such as C1q and C4 are less prominent. Complement factor H–related protein competes with the binding of factor H, a regulator protein, leading to an increase in the activity of the alternate complement pathway.

## ■ DIAGNOSIS REQUIRES CLINICAL SUSPICION AND KIDNEY BIOPSY

Despite advances in understanding the pathogenesis of IgA nephropathy, diagnosis requires a kidney biopsy. Clinical suspicion arises from the presence of acute kidney injury, hematuria, or proteinuria. Uncommonly, patients present with gross hematuria or synpharyngitic hematuria (hematuria with pharyngitis), a presentation seen more often in younger patients (< 40 years).<sup>1</sup> In older populations, IgA nephropathy can be clinically occult with worsening kidney function and microscopic hematuria. While routine screening is common in countries with a high prevalence, such as Japan and China, there are no screening guidelines in the United States. Therefore, timely referral to nephrology upon discovery of hematuria or proteinuria is critical.

Histologic examination of the kidney biopsy specimen with immunofluorescence microscopy will show IgA deposits in the mesangium or capillary loops accompanied by mesangial changes (proliferation and expansion). Serologic markers, while extensively studied and now frequently used in clinical trials, require further validation before they can be applied in the clinic.

Alternative diagnoses must be considered when histopathology reveals IgA staining, as there are numerous mimics of primary IgA nephropathy (Table 1).<sup>1,12–14</sup> Systemic disease states associated with IgA nephropathy, labeled *secondary IgA nephropathy*, include IgA vasculitis, viral infections (human immunodeficiency virus, hepatitis), autoimmune disease (inflammatory bowel disease, psoriasis), cirrhosis, IgA-dominant postinfectious glomerulonephritis, and proliferative glomerulonephritis with monoclonal IgA deposits.

Once the diagnosis is established, the characteristic findings are used to determine prognosis and clinical outcomes. Secondary IgA nephropathy and IgA vasculitis have been largely excluded from clinical trials and carry a different prognosis than primary IgA nephropathy.

## ■ PROGNOSTIC TOOLS

### Oxford Classification of IgA nephropathy

The Oxford Classification of IgA nephropathy was introduced in 2009.<sup>15</sup> The purpose was to create a

standardized histopathologic scoring system using 4 variables that correlate most strongly with patient outcomes, in addition to showing adequate agreement among nephropathologists. The variables are mesangial hypercellularity (M), endocapillary hypercellularity (E), segmental glomerulosclerosis (S), and tubular atrophy/interstitial fibrosis (T), reported as the *MEST score*. The system was updated in 2016 to incorporate crescents (C) to further aid in predicting renal outcomes (Table 2).<sup>15,16</sup>

M, S, and T were found to be independent predictors of glomerular filtration rate (GFR) decline in the original Oxford cohort, but E lesions were not conclusively predictive of decline.<sup>17</sup> Similar associations in GFR decline were seen in patients with endocapillary hypercellularity (E) independent of immunosuppression.<sup>18,19</sup> The Oxford cohort did not control for immunosuppression, leading to a treatment bias. Further, patients with E lesions were more likely to receive immunosuppression. Collectively, this evidence supports the perception that endocapillary lesions are responsive to immunosuppressive treatment and contribute to the decline of kidney function if not treated with immunosuppression.

Although helpful for diagnostic standardization and prognosis, this scoring system does not consider the presence of hypertension, degree of proteinuria, or reduced GFR.

### International IgA nephropathy risk prediction tool



The introduction of the international IgA nephropathy risk prediction tool further refines risk stratification by integrating histologic and clinical factors to predict renal outcomes at the time of biopsy and up to 7 years.<sup>20</sup> It was derived in a multiethnic international cohort with biopsy-proven idiopathic IgA nephropathy and is designed to predict the risk of a 50% decline in estimated GFR or end-stage kidney disease after biopsy.

This web-based prediction tool includes the estimated GFR at the time of biopsy, systolic and diastolic blood pressure at the time of biopsy, proteinuria, age, race, use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, MEST score, immunosuppression use at or before kidney biopsy, and the number of months after a kidney biopsy that the clinician will determine the risk of progressive IgA nephropathy.

Criticisms of the IgA nephropathy prediction tool include its lack of dynamic longitudinal monitoring ability and the absence of modern therapies (endothelin receptor antagonists and sodium-glucose cotrans-



**TABLE 2**  
**Oxford Classification of immunoglobulin A nephropathy: MEST-C score**

Histologic feature	Definition <sup>15,16</sup>	Prognosis	
Mesangial hypercellularity	<p>≥ 4 mesangial cells in any mesangial area of a glomerulus</p> <p>M0: &lt; 50 glomeruli M1: ≥ 50 glomeruli</p>	M1 is predictive of worse outcomes vs M0 <sup>15</sup>	<p>Mesangial hypercellularity and endocapillary proliferation (hematoxylin and eosin stain, magnification ×400)</p> 
Endocapillary proliferation	<p>Increased number of cells in glomerular capillary lumen</p> <p>E0: absent E1: present</p>	<p>E1 is independently associated with worse renal survival in patients who receive no immunosuppression, and does not predict outcomes in studies where patients receive immunosuppression</p> <p>Patients with endocapillary proliferation (E1) are more likely to receive immunosuppression, which is associated with improved outcomes in these patients<sup>16</sup></p>	
Segmental glomerulosclerosis	<p>Adhesion or sclerosis that does not involve the entire glomerulus</p> <p>S0: absent S1: present</p>	S1 is predictive of worse outcomes compared with S0 <sup>15</sup>	
Tubulointerstitial fibrosis	<p>Percentage of tubular atrophy and interstitial fibrosis of cortical area</p> <p>T0: absent or ≤ 25% of tubules T1: 26%–50% of tubules T2: &gt; 50% tubules</p>	Presence of tubulointerstitial fibrosis (T1 or T2) is strongest predictor of adverse renal outcomes <sup>16</sup>	<p>Crescent formation (periodic acid–Schiff stain, magnification ×400)</p> 
Crescents, cellular or fibrocellular	<p>Extracapillary cell proliferation &gt; 2 cell layers and &lt; 50% of matrix</p> <p>C0: absent C1: 1%–24% of glomeruli C2: &gt; 25% of glomeruli</p>	<p>C1 is not predictive if immunosuppression is used</p> <p>C2 is predictive of worse outcomes regardless of immunosuppression<sup>16</sup></p>	

Images courtesy of Leal Herlitz, MD, Cleveland Clinic Anatomic Pathology.

porter [SGLT] 2 inhibitors). Also, it was not validated to guide the use of immunosuppression.<sup>20</sup>

### Proteinuria as an indicator of kidney function

The goal of therapy in IgA nephropathy, as in all kidney disease, is to prevent progression to end-stage kidney disease by decreasing the rate of GFR loss. The main

therapeutic targets in IgA nephropathy include reducing proteinuria and controlling blood pressure. The severity of proteinuria remains the strongest indicator of kidney outcome. The KDIGO (Kidney Disease: Improving Global Outcomes) guidelines<sup>21</sup> recommend reducing proteinuria to less than 1 g per day as a surrogate marker for improved kidney outcome, and consideration of

immunosuppressive therapy if unable to achieve proteinuria levels lower than 1 g per day with conservative management such as RAAS blockade. However, recent large registry data have revealed that 30% of patients with time-averaged proteinuria of 0.44 to less than 0.88 g/g (of creatine) developed kidney failure within 10 years.<sup>22</sup> It is therefore clear that patients with IgA nephropathy and lower degrees of proteinuria may benefit from more intensive disease management.

Currently, the goal of therapy is proteinuria of less than 0.5 g and absence of hematuria. These targets have not been well studied in a prospective therapeutic trial, however, and we do not yet know the risk or benefit of attempting to achieve such targets. Several new trials and therapeutics have emerged that require an update to our approach to diagnosis and treatment of IgA nephropathy.

## CURRENT TREATMENT OPTIONS

### Nonimmunosuppressive therapy

**Treatments targeting RAAS** reduce proteinuria and preserve nephrons across the spectrum of glomerular diseases, including IgA nephropathy. Use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers carries a strong recommendation in the most recent KDIGO guidelines,<sup>21</sup> along with a target blood pressure of 120/70 mm Hg or lower and lifestyle modifications that include smoking cessation, weight reduction, salt restriction (< 2 g/day), and exercise. KDIGO guidelines no longer recommend fish oil for IgA nephropathy.

New nonimmunosuppressive therapy options include the SGLT-2 inhibitors and dual endothelin receptor and angiotensin receptor antagonists.

**SGLT-2 inhibitors.** There have been no dedicated trials to evaluate IgA nephropathy outcomes with the use of these agents. However, IgA nephropathy was well represented in DAPA-CKD (Dapagliflozin in Patients With Chronic Kidney Disease),<sup>23</sup> a randomized controlled trial that evaluated the effect of dapagliflozin in patients with chronic kidney disease and albuminuria due to various causes. In a prespecified analysis of DAPA-CKD, 270 patients with IgA nephropathy treated with dapagliflozin had a 26% reduction in proteinuria compared with placebo. Additionally, the primary outcome (sustained decline in estimated GFR of 50% or more, end-stage kidney disease, or death from a kidney disease–related or cardiovascular cause) occurred in only 6 (4%) participants on dapagliflozin vs 20 (15%) on placebo (hazard ratio 0.29; 95% confidence interval [CI] 0.12–0.73), offering a 71% risk

reduction. Criticisms of this trial include the lack of adequate blood pressure control with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in the run-in period compared with other trials in IgA nephropathy, in addition to recruitment of older patients and exclusion of patients with recent immunosuppression use.


The safety and efficacy of the **dual endothelin and angiotensin receptor antagonist sparsentan** in IgA nephropathy was recently evaluated in the PROTECT (Efficacy and Safety of Sparsentan Versus Irbesartan in Patients With IgA Nephropathy) trial.<sup>24</sup> In this large randomized, active-controlled study, adults with high-risk IgA nephropathy (> 1 g proteinuria per day) received sparsentan or irbesartan 300 mg daily. The primary efficacy end point was a change from baseline to week 36 in the urine protein-creatinine ratio based on a 24-hour urine sample. The sparsentan group saw a 49.8% proteinuria reduction compared with 15.1% in the irbesartan group, which was maintained until the 110-week trial ended. At 2 years, the estimated GFR chronic rate of change (from weeks 6 to 110) was –2.7 mL/min/1.73 m<sup>2</sup>/year with sparsentan and –3.8 mL/min/1.73 m<sup>2</sup>/year with irbesartan (difference 1.1 mL/min/1.73 m<sup>2</sup>/year, 95% CI 0.1–2.1).

The rate of adverse events was similar in the 2 groups, with more hypotension and acute kidney injury occurring in the sparsentan group. Due to the potential hepatotoxicity and fetal toxicity of endothelin receptor antagonists, the FDA requires the Risk Evaluation and Mitigation Strategy for sparsentan, mandating liver function monitoring for patients on the drug and, for those capable of becoming pregnant, maintaining contraception while on treatment and 1 month after. RAAS blockers should be stopped when converting to sparsentan.

On the strength of the 36-week data showing proteinuria reduction, the FDA granted accelerated approval to sparsentan for patients with IgA nephropathy deemed high risk for progression; recently, the drug obtained full approval.

It is currently not known whether the addition of SGLT-2 inhibitors to dual endothelin receptor and angiotensin receptor antagonists or endothelin receptor antagonists will add further proteinuria reduction and estimated GFR benefit. The results of an open-label extension of the PROTECT trial are awaited.

The **endothelin receptor antagonist atrasentan** was recently granted accelerated approval based on findings from the phase 3 ALIGN (Atrasentan in Patients With IgA Nephropathy) trial.<sup>25</sup>



**Figure 2.** Our approach to immunoglobulin (Ig) A nephropathy.

<sup>a</sup>We monitor patients receiving immunosuppressive therapy with assessment of blood pressure and protein-creatinine ratio, renal function panel, and urinalysis every 3 months.

<sup>b</sup>Those with proteinuria  $> 0.5$  g/day.

GFR = glomerular filtration rate; MEST-C = mesangial hypercellularity, endocapillary proliferation, segmental glomerulosclerosis, tubulointerstitial fibrosis, crescents

### Immunosuppressive therapy

Systemic corticosteroids are frequently used in IgA nephropathy, yet their role in management of this disease is controversial. Several randomized controlled trials and meta-analyses that examined corticosteroid use in IgA nephropathy have had conflicting results. Modern randomized controlled trials such as STOP-IgAN (Supportive Versus Immunosuppressive Therapy for the Treatment of Progressive IgA Nephropathy)<sup>26</sup> and TESTING (Therapeutic Evaluation of Steroids in IgA Nephropathy Global)<sup>27</sup> have best represented the use of systemic corticosteroids and their risks, which were likely underreported in older studies.<sup>28</sup>

**STOP-IgAN<sup>26</sup>** was a relatively small randomized controlled trial testing the safety and efficacy of immunosuppressive therapy combined with supportive care compared with supportive care alone. Immunosuppressive therapy consisted of corticosteroids for those with estimated GFR of 60 mL/min/1.73 m<sup>2</sup> or greater, and cyclophosphamide followed by azathioprine and cor-

ticosteroids for those with estimated GFR between 30 and 59 mL/min/1.73 m<sup>2</sup>. Of the 337 patients entering the run-in phase, 106 responded to supportive care after 6 months, which included RAAS blockade, smoking cessation, and cholesterol-lowering with statins; these were not randomized. Only 5% in the supportive-care arm reported complete remission (ie, urine protein-creatinine ratio  $< 0.2$  g/24 hours and stable renal function with a fall in estimated GFR  $< 5$  mL/min/1.73 m<sup>2</sup> from baseline) compared with 17% in the immunosuppressive arm. At the end of the 3-year trial, there was no difference in estimated GFR between the groups. Not surprisingly, immunosuppression with corticosteroids saw higher rates of weight gain, impaired glucose tolerance, and serious adverse events such as infection. STOP-IgAN therefore solidified the value of supportive or nonimmunosuppressive care in IgA nephropathy.

The **TESTING trial** was a randomized clinical trial comparing oral methylprednisolone (0.6–0.8 mg/kg/day for 2 months and then tapering, with a treatment period

of 6 to 8 months) with placebo, carried out in a predominantly East Asian population.<sup>27</sup> While methylprednisolone resulted in a lower likelihood of the primary end point (40% decline in estimated GFR, end-stage kidney disease, or death due to kidney failure), it came at the price of serious infections, including 2 infection-related deaths, and the investigators suspended the trial.

The trial resumed recruitment after the methylprednisolone dose was reduced (0.4 mg/kg/day for 2 months, tapered over 6 to 9 months) and prophylactic antibiotics were mandated.<sup>29</sup> The primary composite end point occurred in 28.8% (74 patients) of the methylprednisolone group vs 43.1% (106) of the placebo group (hazard ratio 0.53, 95% CI 0.39–0.72,  $P < .001$ ) over a mean follow-up of 4.2 years. Despite the reduced steroid dose, serious adverse events were 4 times higher in the methylprednisolone group than in the placebo group: 37 vs 8 total events that occurred in 28 (10.9%) vs 7 (2.8%) participants.

Finally, **targeted-release formulation (TRF) budesonide** is the only immunosuppressive drug fully approved by the FDA to treat IgA nephropathy. The hypothesis is that TRF budesonide is delivered directly to the small bowel and Peyer patches, where the galactose-deficient IgA is produced, interrupting a key mediator of IgA nephropathy. In theory, because of extensive first-pass metabolism, less drug would reach the systemic circulation and limit glucocorticoid toxicity.

The NefIgArd (Efficacy and Safety of Nefecon in Patients With Primary IgA [Immunoglobulin A] Nephropathy) trial,<sup>30</sup> a phase 3 randomized trial, evaluated TRF budesonide vs placebo in patients with proteinuria of 1 g or more over a 9-month period. TRF budesonide resulted in significantly reduced proteinuria and sustained estimated GFR benefit over a 2-year follow-up. However, like other trials of systemic corticosteroids for IgA nephropathy, the proteinuria returned after TRF budesonide was stopped, and steroid-related side effects were more common in the TRF budesonide group, including weight gain, facial edema, acne, peripheral edema, and hypertension.

### Treatment recommendations

The landscape for treatment of IgA nephropathy has changed rapidly and will continue to change in the coming months and years. **Figure 2**<sup>26,27,31</sup> presents the authors' recommended approach, with these considerations:

- A proteinuria threshold of 0.5 g/day is the new cutoff for warranting a biopsy, as opposed to the traditional value of 1 g/day or greater.
- While the MEST-C score cannot be used to guide

immunosuppressive therapy, we advise considering it in addition to a direct discussion with the renal pathologist who interpreted the biopsy.

- Nonimmunosuppressive therapy should be considered in conjunction with immunosuppressive therapy.
- There is inadequate evidence to support superiority of TRF budesonide over systemic corticosteroids, and this decision is made on a case-by-case basis.

Note that this approach can include use of mycophenolate mofetil as a corticosteroid-free immunosuppressive option. A randomized trial of 170 Chinese patients with IgA nephropathy showed mycophenolate mofetil when added to supportive care (renin-angiotensin system blockade) reduced the risk of the primary composite outcome (doubling of serum creatinine, end-stage kidney disease, or death due to kidney or cardiovascular cause) compared with supportive care alone.<sup>31</sup>

### FUTURE TREATMENT OPTIONS

A variety of treatment options are under investigation for the management of IgA nephropathy targeting the different “hits” in the pathogenesis model (**Table 3**).<sup>24,25,30,32–47</sup>

**Complement inhibitors.** Significant research is focused on the complement cascade, reflecting the key role of the complement system in the development of IgA nephropathy. Several complement inhibitors are being studied in phase 2 and 3 trials, with mixed results.<sup>32–40</sup> There has been much focus on inhibition of the alternative pathway of complement, which impacts the deposition of immune complexes in the glomerulus (the fourth hit in the pathogenesis model of IgA nephropathy).

Iptacopan (LNP023), an oral factor B inhibitor that prevents the activity of the alternative pathway C3 convertase, was evaluated in 66 patients with IgA nephropathy in a phase 2 trial.<sup>32</sup> At 6 months, participants who received iptacopan 200 mg twice daily had a 40% reduction in proteinuria compared with placebo. In a follow-up phase 3 trial, iptacopan showed a significant reduction in proteinuria at 9 months compared with placebo.<sup>38</sup> It was recently granted accelerated approval by the FDA.

The complement inhibitor class of drugs will likely be used in cases of IgA nephropathy that are resistant to traditional treatments, including corticosteroids, and have a significant inflammatory component on kidney biopsy, or those where a steroid-sparing regimen is ideal. There is interest in correlating the intensity



TABLE 3

**Recently approved and future treatment options for immunoglobulin A nephropathy**

	Drugs	Status
<b>Recent approvals</b>	Endothelin and angiotensin receptor antagonist: sparsentan <sup>24</sup>	Full approval
	Endothelin receptor antagonist: atrasentan <sup>25</sup>	Accelerated approval
	Corticosteroid: targeted-release formulation budesonide <sup>30</sup>	Full approval
	Complement inhibitor: iptacopan <sup>32,38</sup>	Accelerated
<b>Future (not approved) treatment options</b>	Complement inhibitors <sup>33–35,37,39,40</sup>	
	Avacopan, ravulizumab, cemdisiran, vemircopan, pegcetacoplan	Phase 2 and 3 trials in progress
	IONIS-Fb-LRx	Phase 3 trial in progress
	Narsoplimab	Phase 3 negative trial
	R07434656	Phase 3 trial in progress
	ARO-C3	Phase 1 trial in progress
	B-cell-depleting therapies <sup>41–45</sup>	
	Atacicept	Phase 3 trial in progress
	Sibeprenlimab, zigakibart, telitacicept	Phase 2 and 3 trials in progress
	Plasma cell inhibitors <sup>46,47</sup>	
	Felzartamab, mezagitamab, bortezomib	Phase 2 trials in progress

of C3 staining on immunofluorescence microscopy of kidney biopsies and the potential response to complement inhibition.

**Inhibition of antibody-producing B cells** (targeting the second and third hits in IgA nephropathy pathogenesis) has also emerged as a therapeutic target for the management of IgA nephropathy. While rituximab has not been shown to be beneficial, other B-cell receptor targets have shown some initial success, including APRIL (a proliferation-inducing ligand), BAFF (B-cell activating factor), and plasma cell receptors.<sup>48,49</sup> APRIL and BAFF regulate B-cell survival.

APRIL may help to specifically produce IgA1 molecules by controlling the immunoglobulin class switch recombination.<sup>48,49</sup> Several monoclonal antibodies against APRIL are currently under investigation, including sibeprenlimab, zigakibart, and atacicept.<sup>41–45</sup> A phase 2b clinical trial of atacicept showed a significant reduction in proteinuria compared with placebo, and a phase 3 clinical trial is under way.<sup>44</sup>

**Antiplasma cell therapies** (second and third hits in IgA nephropathy pathogenesis) are also being investigated as potential treatment options.<sup>46,47</sup> Monoclonal antibodies to CD38 (felzartamab and mezagitamab) are being assessed in early-stage clinical trials.<sup>46</sup> Larger studies are needed to assess the efficacy of this approach in the management of IgA nephropathy.

## NEW UNDERSTANDING AND NEW CHALLENGES

Advances in our understanding of the pathogenesis, prognosis, and, most important, therapeutic options for IgA nephropathy have been significant. For decades, treatment options have been limited, with many reaching end-stage kidney disease within their lifetime. Recognition of the disease still depends on urinalysis and quantification of proteinuria, but with new therapies on the horizon, there is hope that awareness will increase.

For the treating clinician, the management of IgA nephropathy is a complex clinical scenario. The 4-hit model provides a blueprint for the pathogenesis, allowing targeted management of the disease, but appropriate use of novel therapies and assessment of response remain significant challenges. Among the questions to consider are the following:

- How should these drugs be combined, if at all?
- How long should each therapy be given?
- Do newer therapies result in a true reduction in the rate of end-stage kidney disease?

Also important are conversations for patients and clinicians on cost and access to therapy. Ongoing study, debate, and conversation within the nephrology community are needed to prioritize these novel therapies and develop guidelines.

## DISCLOSURES

Dr. Cohen has disclosed consulting for Gilead Sciences, Inc. Dr. Cavanaugh has disclosed consulting for Cerium Pharmaceuticals, Trave Therapeutics, and Vera Therapeutics, and serving as an advisor or review panel participant for Cerium Pharmaceuticals. Dr. Ramsawak and Dr. Linares report no relevant financial relationships which, in the context of their contributions, could be perceived as a potential conflict of interest.

## REFERENCES

1. **Pattrapornpisut P, Avila-Casado C, Reich HN.** IgA nephropathy: core curriculum 2021. *Am J Kidney Dis* 2021; 78(3):429–441. doi:10.1053/j.ajkd.2021.01.024
2. **Robert T, Berthelot L, Cambier A, Rondeau E, Monteiro RC.** Molecular insights into the pathogenesis of IgA nephropathy. *Trends Mol Med* 2015; 21(12):762–775. doi:10.1016/j.molmed.2015.10.003
3. **Thompson A, Carroll K, A Inker L, et al.** Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. *Clin J Am Soc Nephrol* 2019; 14(3):469–481. doi:10.2215/CJN.08600718
4. **Rizk DV, Saha MK, Hall S, et al.** Glomerular immunodeposits of patients with IgA nephropathy are enriched for IgG autoantibodies specific for galactose-deficient IgA1. *J Am Soc Nephrol* 2019; 30(10):2017–2026. doi:10.1681/ASN.2018111156
5. **Gharavi AG, Moldoveanu Z, Wyatt RJ, et al.** Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. *J Am Soc Nephrol* 2008; 19(5):1008–1014. doi:10.1681/ASN.2007091052
6. **Selvaskandan H, Barratt J, Cheung CK.** Immunological drivers of IgA nephropathy: exploring the mucosa-kidney link. *Int J Immunogenet* 2022; 49(1):8–21. doi:10.1111/iji.12561
7. **Rollino C, Vischini G, Coppo R.** IgA nephropathy and infections. *J Nephrol* 2016; 29(4):463–468. doi:10.1007/s40620-016-0265-x
8. **Gleeson PJ, Benech N, Chemouny J, et al.** The gut microbiota post-translationally modifies IgA1 in autoimmune glomerulonephritis. *Sci Transl Med* 2024; 16(740):ead6149. doi:10.1126/scitranslmed.adl6149
9. **Rauterberg EW, Lieberknecht HM, Wingen AM, Ritz E.** Complement membrane attack (MAC) in idiopathic IgA-glomerulonephritis. *Kidney Int* 1987; 31(3):820–829. doi:10.1038/ki.1987.72
10. **Lai KN, Leung JC, Chan LY, et al.** Podocyte injury induced by mesangial-derived cytokines in IgA nephropathy. *Nephrol Dial Transplant* 2009; 24(1):62–72. doi:10.1093/ndt/gfn441
11. **Maillard N, Wyatt RJ, Julian BA, et al.** Current understanding of the role of complement in IgA nephropathy. *J Am Soc Nephrol* 2015; 26(7):1503–1512. doi:10.1681/ASN.2014101000
12. **Tota M, Baron V, Musial K, et al.** Secondary IgA nephropathy and IgA-associated nephropathy: a systematic review of case reports. *J Clin Med* 2023; 12(7):2726. doi:10.3390/jcm12072726
13. **Wallace E, Maillard N, Ueda H, et al.** Immune profile of IgA-dominant diffuse proliferative glomerulonephritis. *Clin Kidney J* 2014; 7(5):479–483. doi:10.1093/ckj/sfu090
14. **Bridoux F, Javaugue V, Nasr SH, Leung N.** Proliferative glomerulonephritis with monoclonal immunoglobulin deposits: a nephrologist perspective. *Nephrol Dial Transplant* 2021; 36(2):208–215. doi:10.1093/ndt/gfz176
15. **Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran DC, Coppo R, et al.** The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. *Kidney Int* 2009; 76(5):534–545. doi:10.1038/ki.2009.243
16. **Trimarchi H, Barratt J, Cattran DC, et al.** Oxford classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. *Kidney Int* 2017; 91(5):1014–1021. doi:10.1016/j.kint.2017.02.003
17. **Alamartine E, Sauron C, Laurent B, Sury A, Seffert A, Mariat C.** The use of the Oxford classification of IgA nephropathy to predict renal survival. *Clin J Am Soc Nephrol* 2011; 6(10):2384–2388. doi:10.2215/CJN.01170211
18. **Chakera A, MacEwen C, Bellur SS, Chompuk LO, Lunn D, Roberts ISD.** Prognostic value of endocapillary hypercellularity in IgA nephropathy patients with no immunosuppression. *J Nephrol* 2016; 29(3):367–375. doi:10.1007/s40620-015-0227-8
19. **Haaskjold YL, Bjørneklett R, Bostad L, Bostad LS, Lura NG, Knoop T.** Utilizing the MEST score for prognostic staging in IgA nephropathy. *BMC Nephrol* 2022; 23(1):26. doi:10.1186/s12882-021-02653-y
20. **Barbour SJ, Coppo R, Zhang H, et al.** Evaluating a new international risk-prediction tool in IgA nephropathy [published correction appears in *JAMA Intern Med* 2019; 179(7):1007]. *JAMA Intern Med* 2019; 179(7):942–952. doi:10.1001/jamainternmed.2019.0600
21. **Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group.** KDIGO 2021 clinical practice guideline for the management of glomerular diseases. *Kidney Int* 2021; 100(4S):S1–S276. doi:10.1016/j.kint.2021.05.021
22. **Pitcher D, Braddon F, Hendry B, et al.** Long-term outcomes in IgA nephropathy. *Clin J Am Soc Nephrol* 2023; 18(6):727–738. doi:10.2215/CJN.0000000000000135
23. **Wheeler DC, Toto RD, Stefánsson BV, et al.** A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. *Kidney Int* 2021; 100(1):215–224. doi:10.1016/j.kint.2021.03.033
24. **Rovin BH, Barratt J, Heerspink HJL, et al.** Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. *Lancet* 2023; 402(10417):2077–2090. doi:10.1016/S0140-6736(23)02302-4
25. **Heerspink HJL, Jardine M, Kohan DE, et al.** Atrasentan in patients with IgA nephropathy. *N Engl J Med* 2025; 392(6):544–554. doi:10.1056/NEJMoa2409415
26. **Rauen T, Eitner F, Fitzner C, et al.** Intensive supportive care plus immunosuppression in IgA nephropathy. *N Engl J Med* 2015; 373(23):2225–2236. doi:10.1056/NEJMoa1415463
27. **Lv J, Zhang H, Wong MG, et al.** Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. *JAMA* 2017; 318(5):432–442. doi:10.1001/jama.2017.9362
28. **Natale P, Palmer SC, Ruospo M, et al.** Immunosuppressive agents for treating IgA nephropathy. *Cochrane Database Syst Rev* 2020; 3(3):CD003965. doi:10.1002/14651858.CD003965.pub3
29. **Lv J, Wong MG, Hladunewich MA, et al.** Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial. *JAMA* 2022; 327(19):1888–1898. doi:10.1001/jama.2022.5368
30. **Lafayette R, Kristensen J, Stone A, et al.** Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial [published correction appears in *Lancet* 2023; 402(10405):850]. *Lancet* 2023; 402(10405):859–870. doi:10.1016/S0140-6736(23)01554-4
31. **Hou FF, Xie D, Wang J, et al.** Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: a randomized clinical trial. *JAMA Netw Open* 2023; 6(2):e2254054. doi:10.1001/jamanetworkopen.2022.54054
32. **Zhang H, Rizk DV, Perkovic V, et al.** Results of a randomized double-blind placebo-controlled phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy. *Kidney Int* 2024; 105(1):189–199. doi:10.1016/j.kint.2023.09.027
33. **Bruchfeld A, Magin H, Nachman P, et al.** C5a receptor inhibitor avacopan in immunoglobulin A nephropathy—an open-label pilot study. *Clin Kidney J* 2022; 15(5):922–928. doi:10.1093/ckj/sfab294
34. **Lafayette RA, Rovin BH, Reich HN, Tumlin JA, Floege J, Barratt J.** Safety, tolerability and efficacy of narsoplimab, a novel MASP-2 inhibitor for the treatment of IgA nephropathy. *Kidney Int Rep* 2020; 5(11):2032–2041. doi:10.1016/j.ekir.2020.08.003
35. **Barratt J, Valdivia MAP, Roccatello D, Garlo K, Rice K, Lafayette R.** WCN24-1197: Efficacy and safety of ravulizumab in a phase 2 randomized controlled trial in IgA nephropathy (abstract). *Kidney Int Rep* 2024; 9(4):S155–S156.

36. Lim RS, Yeo SC, Barratt J, Rizk DV. An update on current therapeutic options in IgA nephropathy. *J Clin Med* 2024; 13(4):947. doi:10.3390/jcm13040947
  37. Omeros Corporation. Omeros Corporation provides update on interim analysis of ARTEMIS-IgAN phase 3 trial of narsoplimab in IgA nephropathy. October 16, 2023. <https://investor.omeros.com/news-releases/news-release-details/omeros-corporation-provides-update-interim-analysis-artemis-igan>. Accessed May 15, 2025.
  38. Perkovic V, Kollins D, Renfurum R, et al. WCN24-1506: Efficacy and safety of iptacopan in patients with IgA nephropathy: interim results from the phase 3 APPLAUSE-IgAN study (abstract). *Kidney Int Rep* 2024; 9(4):S506.
  39. Arrowhead Pharmaceuticals. Arrowhead announces interim results from ongoing phase 1/2 study of ARO-C3 for treatment of complement mediated diseases. February 28, 2023. <https://ir.arrowhead-pharma.com/news-releases/news-release-details/arrowhead-announces-interim-results-ongoing-phase-12-study-aro>. Accessed May 15, 2025.
  40. Barratt J, Flöge J, Duggal V, et al. WCN24-912: IMAGINATION: a global phase III trial of R07434656, an antisense oligonucleotide inhibitor of complement factor b, in IgA nephropathy. *Kidney Int Rep* 2024; 9(4):S147.
  41. Mathur M, Barratt J, Chacko B, et al. A phase 2 trial of sibeprenlimab in patients with IgA nephropathy. *N Engl J Med* 2024; 390(1):20–31. doi:10.1056/NEJMoa2305635
  42. Barratt J, Hour B, Kooienga L et al. POS-109: Interim results of phase 1 and 2 trials to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of bion-1301 in patients with IgA nephropathy (abstract). *Kidney Int Rep* 2022; 7(2):S46.
  43. Barratt J, Tumlin J, Suzuki Y, et al. Randomized phase II JANUS study of atacicept in patients with IgA nephropathy and persistent proteinuria. *Kidney Int Rep* 2022; 7(8):1831–1841. doi:10.1016/j.ekir.2022.05.017
  44. Lafayette R, Maes B, Lin C, et al. #3848 ORIGIN Trial: 24-wk primary analysis of a randomized, double-blind, placebo-controlled PH2B study of atacicept in patients with IgAN (abstract). *Nephrol Dial Transplant* 2023; 38(suppl 1):i23.
  45. Lv J, Liu L, Hao C, et al. Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria. *Kidney Int Rep* 2022; 8(3):499–506. doi:10.1016/j.ekir.2022.12.014
  46. Maixnerova D, El Mehdi D, Rizk DV, Zhang H, Tesar V. New treatment strategies for IgA nephropathy: targeting plasma cells as the main source of pathogenic antibodies. *J Clin Med* 2022; 11(10):2810. doi:10.3390/jcm11102810
  47. Hartono C, Chung M, Perlman AS, et al. Bortezomib for reduction of proteinuria in IgA nephropathy. *Kidney Int Rep* 2018; 3(4): 861–866. doi:10.1016/j.ekir.2018.03.001
  48. Cheung CK, Barratt J, Carroll K, et al. Targeting APRIL in the treatment of IgA nephropathy. *Clin J Am Soc Nephrol* 2024; 19(3): 394–398. doi:10.2215/CJN.0000000000000338
  49. Zhai YL, Zhu L, Shi SF, Liu LJ, Lv JC, Zhang H. Increased APRIL expression induces IgA1 aberrant glycosylation in IgA nephropathy. *Medicine (Baltimore)* 2016; 95(11):e3099. doi:10.1097/MD.0000000000003099
- .....
- Address:** Seshma Ramsawak, MD, Department of Kidney Medicine, Cleveland Clinic, 9500 Euclid Avenue, Cleveland OH, 44195; [ramsa@s.ccf.org](mailto:ramsa@s.ccf.org)